Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Lea Dutta, Min Ren, Emmett V. Schmidt, Robert Orlowski, Jodi Alicia McKenzie, Kathryn Gillis, Antonio Casado Herraez
Institutions: Memorial Sloan Kettering Cancer Center, Providence Portland Medical Center, Vall d'Hebron Institute of Oncology, Beth Israel Deaconess Medical Center, Rocky Mountain Cancer Centers, Institut Català d'Oncologia, MD Anderson Cancer Center Madrid, Abramson Cancer Center, University of Pennsylvania, Arizona Oncology, Texas Oncology, Eisai (United States), Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3032381833